Max Chat
Company Analysis Universe Pharmaceuticals INC
1. Summary
Advantages
- The stock's return over the last year (23.99%) is higher than the sector average (0%).
- Current debt level 10.29% is below 100% and has decreased over 5 years from 14.04%.
Disadvantages
- Price (3.98 $) is higher than fair price (3.98 $)
- Dividends (0%) are below the sector average (0.527%).
- The company's current efficiency (ROE=-15.59%) is lower than the sector average (ROE=14.17%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Universe Pharmaceuticals INC | Healthcare | Index | |
|---|---|---|---|
| 7 days | -3.2% | 1.9% | 1.6% |
| 90 days | 13.1% | -15.7% | 31% |
| 1 year | 24% | 0% | 12.3% |
UPC vs Sector: Universe Pharmaceuticals INC has outperformed the "Healthcare" sector by 23.99% over the past year.
UPC vs Market: Universe Pharmaceuticals INC has outperformed the market by 11.65% over the past year.
Stable price: UPC is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: UPC with weekly volatility of 0.4613% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (3.98 $) is higher than the fair price (3.98 $).
Price is higher than fair: The current price (3.98 $) is 0% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (64.31).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (89.99).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.1018) is lower than that of the sector as a whole (18.97).
P/BV vs Market: The company's P/BV (0.1018) is lower than that of the market as a whole (9.37).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0.1245) is lower than that of the sector as a whole (32.77).
P/S vs Market: The company's P/S indicator (0.1245) is lower than that of the market as a whole (10.11).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-1.15) is lower than that of the sector as a whole (274.86).
EV/Ebitda vs Market: The company's EV/Ebitda (-1.15) is lower than that of the market as a whole (51.19).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -36.22% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-36.22%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).
5.4. ROE
ROE vs Sector: The company's ROE (-15.59%) is lower than that of the sector as a whole (14.17%).
ROE vs Market: The company's ROE (-15.59%) is lower than that of the market as a whole (11.64%).
5.5. ROA
ROA vs Sector: The company's ROA (-11.57%) is lower than that of the sector as a whole (1.18%).
ROA vs Market: The company's ROA (-11.57%) is lower than that of the market as a whole (6.89%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (11.01%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.527%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
